Possible New Treatment for CF and NTM
Trial Objectives
Researchers in the ABATE Study are testing the safety of a drug called gallium nitrate for people with cystic fibrosis (CF) who also have been diagnosed with nontuberculous mycobacteria (NTM). Gallium nitrate is currently FDA-approved to treat high calcium in blood caused by cancer. Its use in treating people with CF is experimental, but gallium nitrate is thought to have antimicrobial properties that would help resolve NTM infections.
Who Can Participate
Adults 18 and older with CF and NTM who have a lung function of 25% or higher. To qualify, participants must not have received NTM treatment for at least two years.
Age: 18+ Gender: Any
Estimated Time Commitment
8 in-person visits, including two 5-day inpatient stays, and 4 phone calls over 28 weeks
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Christopher H. Goss, MD MSc (University of Washington, Seattle Children's Hospital)
Principal Investigators
Jerry A. Nick, MD
Co-Investigators
-
Jane E. Gross, MD, PhD
-
Katherine Hisert, MD, PhD
-
Jennifer L. Taylor-Cousar, MD, MSCS